Results 61 to 70 of about 49,526 (230)

Enriching Higher Affinity Aptamers by Addressing the Kinetic Aspect of the DNA Strand‐Displacement Reaction

Angewandte Chemie, Volume 138, Issue 5, 28 January 2026.
Capture‐SELEX for ampicillin aptamers led to the dominance of a low‐affinity aptamer, while extending the target‐library incubation time significantly increased the abundance of a high‐affinity aptamer, revealing a previously unrecognized kinetic effect in the DNA strand displacement reaction during SELEX.
Yuzhe Ding, Yicheng Heng, Ka‐Ying Wong, Qingyu Chen, Juewen Liu   +4 more
wiley   +2 more sources

Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database

Scientific Reports
Voriconazole is a second-generation azole used to treat serious fungal infections. Visual hallucinations constitute a representative adverse event caused by voriconazole. However, its mechanism of action remains unclear. In patients with schizophrenia or
Hideo Kato, Chihiro Shiraishi, Mao Hagihara, Hiroshige Mikamo, Takuya Iwamoto   +4 more
doaj   +1 more source

Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child–Pugh class B and C cirrhosis: A multicenter study

International Journal of Infectious Diseases, 2018
Objectives: The purpose of this study was to investigate the pharmacokinetic profile and safety of voriconazole treatment in patients with Child–Pugh class B and C cirrhosis. Methods: Liver cirrhosis patients who had received the recommended voriconazole
Taotao Wang, Miao Yan, Dan Tang, Ling Xue, Tao Zhang, Yuzhu Dong, Li Zhu, Xinggang Wang, Yalin Dong   +8 more
doaj   +1 more source

Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever [PDF]

, 2002
Background Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections.
Donowitz, Gerald, Greenberg, Richard, Lazarus, Hillard M., Lee, Jeanette, Pappas, Peter, Petersen, Finn, Raffalli, John, Stiff, Patric, Walsh, Thomas J., Winston, Drew J., Yanovich, Saul   +10 more
core   +2 more sources

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta, Tong Wang, Susmita, Ditte Marie L. Saunte, Roderick Hay, Vincent Piguet   +5 more
wiley   +1 more source

Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study

Frontiers in Pharmacology
BackgroundThe concomitant use of nirmatrelvir/ritonavir and voriconazole is generally contraindicated in clinical practice because of drug‒drug interactions (DDIs).
Hao Shi, Xuan Zhang, Qihui Kong, Lingyan Yu, Zhenwei Yu, Zhenwei Yu, Zhenwei Yu   +6 more
doaj   +1 more source

Voriconazole-induced hypokalemia and hyponatremia and their correlations with voriconazole trough concentration

Di-san junyi daxue xuebao, 2020
Objective To investigate the incidence rates of voriconazole-induced hypokalemia and hyponatremia and their correlations with voriconazole trough concentration in the patients with lung invasive aspergillosis.
CHENG Lin, WENG Bangbi, XIANG Rongfeng, XIA Peiyuan   +3 more
doaj   +1 more source

Decrease of voriconazole trough levels during therapy with enteral nutrition: a case report [PDF]

, 2022
Hiromi Kaneko, Shingo Yamazaki, Masashi Uchida, Takaaki Suzuki, Kentaro Murakami, Hisahiro Matsubara, Katsuhiko Kamei, Itsuko Ishii   +7 more
openalex   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis

Frontiers in Pharmacology
Voriconazole is a broad-spectrum triazole antifungal agent. A number of studies have revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was associated with the CYP2C19 phenotype. However, the combined effects of CYP2C19
Jing Ling, Xuping Yang, Lulu Dong, Yan Jiang, Sulan Zou, Nan Hu   +5 more
doaj   +1 more source